Cencora, Inc.

Valuation Analysis

About the Company

Cencora, Inc. en bref

Cencora, Inc. (COR) is currently trading at 237,27 € with a market capitalization of 46,2 Md €. The trailing P/E ratio stands at 20.82x, with a forward P/E of 13.74x. The 52-week range spans from 213,65 € to 329,47 €; the current price is 28% below the yearly high. Year-over-year revenue growth stands at +3.8%. The net profit margin stands at 0.78%.

💰 Dividende

Cencora, Inc. pays an annual dividend of 2,09 € per share, representing a yield of 0.88%. The payout ratio stands at 17.62%.

📊 Avis des analystes

12 analystes évaluent Cencora, Inc. (COR) au consensus : Acheter. L'objectif de cours moyen est de 305,94 €, soit un potentiel de +28.94% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 244,35 € à 359,54 €.

Cencora, Inc. : la thèse d'investissement en détail

Cencora, Inc. (COR) operates in the Healthcare — specifically Medical Distribution — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 128.3% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Return on equity of 107.13% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Wall Street consensus sits at Buy with an average price target implying roughly 28.94% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 3.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 0.78%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 420.99% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

With a PEG ratio of 0.6, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 13.74x is meaningfully below the trailing 20.82x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 28.94% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Cencora, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.